Evidence map›Paper›PMID 38265374›Full record

ReviewInfectious disorders drug targets2024

Lipika Singhal, Diljot Sandhu, Varsha Gupta, Ivneet Kour

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infectious disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Prevalence of the Antibiotic Resistance ofOpen forum infectious diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lipika SinghalDepartment of Microbiology, Government Medical College & Hospital, Chandigarh, 160030, India.
Diljot SandhuDepartment of Microbiology, Government Medical College & Hospital, Chandigarh, 160030, India.
Varsha GuptaDepartment of Microbiology, Government Medical College & Hospital, Chandigarh, 160030, India.
Ivneet KourDepartment of Microbiology, Government Medical College & Hospital, Chandigarh, 160030, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTyphoid fever poses a significant health challenge in low- and middleincome countries (LMiCs), impacting millions of individuals across various age groups. Its prevalence is particularly pronounced in South Asia. Factors contributing to its transmission in South Asia include rapid unplanned urbanization, urban-rural disparities, provision of poor water and sanitation facilities, and open defecation. The mortality rate of typhoid fever is up to 1%, and those who survive have a protracted period of poor health and carry an enormous financial burden. The treatment is further complicated by the emerging antibiotic resistance leaving few treatment options in hands. This issue has become more urgent due to the further emergence of extended drug-resistant (XDR) and multidrug-resistant (MDR) typhoid strains, as well as their subsequent global spread. Fluoroquinolone-resistant

Indexed as

Anti-Bacterial AgentsDeveloping CountriesDrug Resistance, Multiple, BacterialMicrobial Sensitivity TestsSalmonella typhiTyphoid FeverFluoroquinolonesHumansAnti-Bacterial AgentsFluoroquinoloneshealthmultidrug-resistant.pronouncedrapid unplannedSalmonella TyphiTyphoid fever extended drug-resistant

Identifiers

PMID38265374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.